The Possible Protective Effect of Metformin in COVID-19 Infection

Main Article Content

Waleed K. Abdulsahib


Coronavirus 2019 (COVID-19) infections with more than 30 million confirmed cases are increasing rapidly, requiring urgent and safe treatment. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a virus responsible for the infection of COVID-19. Metformin (M) is a biguanide drug used as a first choice for the management of hyperglycemia in type 2 diabetes mellitus (T2DM). Furthermore, it is safe and currently available. It is speculated that metformin can be used for T2DM patients with COVID-19, because in addition to its hypoglycemic effect, this biguanide also shows many beneficial effects, including anti-inflammatory effects and cardiopulmonary protection especially by angiotensin converting enzyme 2 (ACE2) targeting. Therefore, the reasons for the use of metformin in COVID-19 patients were discussed in this study. Metformin has a promising role in treatment of COVID-19 in T2DM and obese women patients.

COVID-19, type 2 diabetes mellitus, metformin, angiotensin converting enzyme 2.

Article Details

How to Cite
Abdulsahib, W. K. (2020). The Possible Protective Effect of Metformin in COVID-19 Infection. Journal of Advances in Medical and Pharmaceutical Sciences, 22(8), 1-5.
Review Article


Dashboard WCD (COVID-19). No Title [Internet]. 2020.

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–20.

Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med. 2020;9(5):1417.

Kathem SH, AbouAlaiwi WA, Zi X, Nauli SM. Capillary endothelia from two ADPKD patients are polyploidy. Ann Clin Cytol Pathol. 2016;2(2).

Abood SJ, Abdulsahib WK, Hussain SA, Ismail SH. Melatonin Potentiates the Therapeutic Effects of Metformin in Women with Metabolic Syndrome. Sci Pharm. 2020;88(2):28.

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (80-). 2020;367(6483):1260–3.

Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al. The ACE2/angiotensin-(1–7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1–7). Physiol Rev. 2018;98(1):505–53.

Reddy R, Asante I, Liu S, Parikh P, Liebler J, Borok Z, et al. Circulating angiotensin peptides levels in acute respiratory distress syndrome correlate with clinical outcomes: a pilot study. PLoS One. 2019;14(3):e0213096.

Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell; 2020.

Zhang J, Dong J, Martin M, He M, Gongol B, Marin TL, et al. AMP-activated protein kinase phosphorylation of angiotensin-converting enzyme 2 in endothelium mitigates pulmonary hypertension. Am J Respir Crit Care Med. 2018;198(4):509–20.

Malhotra A, Hepokoski M, McCowen KC, Shyy JYJ. ACE2, Metformin, and COVID-19. iScience. 2020;101425.

Yu S, Christiani DC, Thompson BT, Bajwa EK, Gong MN. Role of diabetes in the development of acute respiratory distress syndrome. Crit Care Med. 2013;41(12):2720.

Mortaz E, Alipoor SD, Adcock IM, Mumby S, Koenderman L. Update on neutrophil function in severe inflammation. Front Immunol. 2018;9:2171.

Eilenberg W, Stojkovic S, Piechota-Polanczyk A, Kaider A, Kozakowski N, Weninger WJ, et al. Neutrophil gelatinase associated lipocalin (NGAL) is elevated in type 2 diabetics with carotid artery stenosis and reduced under metformin treatment. Cardiovasc Diabetol. 2017;16(1):1–11.

Soraya H, Rameshrad M, Mokarizadeh A, Garjani A. Metformin attenuates myocardial remodeling and neutrophil recruitment after myocardial infarction in rat. BioImpacts BI. 2015;5(1):3.

Chen X, Walther FJ, Sengers RMA, Laghmani EH, Salam A, Folkerts G, et al. Translational Research in Acute Lung Injury and Pulmonary Fibrosis: Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response. Am J Physiol Cell Mol Physiol. 2015;309(3):L262.

Dalan R. Metformin, neutrophils and COVID-19 infection. Diabetes Res Clin Pract; 2020.

Kelly B, Tannahill GM, Murphy MP, O’Neill LAJ. Metformin inhibits the production of reactive oxygen species from NADH: ubiquinone oxidoreductase to limit induction of interleukin-1β (IL-1β) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages. J Biol Chem. 2015;290(33):20348–59.

Matsiukevich D, Piraino G, Lahni P, Hake PW, Wolfe V, O’Connor M, et al. Metformin ameliorates gender-and age-dependent hemodynamic instability and myocardial injury in murine hemorrhagic shock. Biochim Biophys Acta (BBA)- Molecular Basis Dis. 2017;1863(10):2680–91.

Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20(2).

Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med; 2020.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395(10229):1033.

Park JW, Lee JH, Park YH, Park SJ, Cheon JH, Kim WH, et al. Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients. World J Gastroenterol. 2017;23(28):5196.

Vemuri R, Sylvia KE, Klein SL, Forster SC, Plebanski M, Eri R, et al. The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. In: Seminars in immunopathology. Springer. 2019;265–75.

Conti P, Ronconi G, Caraffa AL, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):1.

Mackey E, Ayyadurai S, Pohl CS, D’Costa S, Li Y, Moeser AJ. Sexual dimorphism in the mast cell transcriptome and the pathophysiological responses to immunological and psychological stress. Biol Sex Differ. 2016;7(1):60.

Scheen AJ. Metformin and COVID-19: From cellular mechanisms to reduced mortality. Diabetes Metab; 2020.

Singh AK, Khunti K. Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A Narrative Review. Diabetes Res Clin Pract; 2020.

EL‐Arabey AA, Abdalla M. Metformin and COVID‐19: A novel deal of an Old Drug. J Med Virol; 2020.

Esam Z. A proposed mechanism for the possible therapeutic potential of metformin in COVID-19. Diabetes Res Clin Pract; 2020.

Grant PJ. The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects. Diabete Metab. 1991;17(1 Pt 2):168–73.

Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C, et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res. 2016;119(5):652–65.

Tsoyi K, Jang HJ, Nizamutdinova IT, Kim YM, Lee YS, Kim HJ, et al. Metformin inhibits HMGB1 release in LPS‐treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol. 2011;162(7):1498–508.

Bramante C, Ingraham N, Murray T, Marmor S, Hoversten S, Gronski J, et al. Observational study of metformin and risk of mortality in patients hospitalized with Covid-19. MedRxiv; 2020.